BTIG Starts Coverage on Alto Neuroscience with Buy Rating and $27 Target

BTIG initiates coverage of Alto Neuroscience with a Buy rating and $27 price target, highlighting innovative biomarkers and upcoming data readouts in psychiatric drug development.